使用修改的马克曼输液方案作为主要预防的帕克利塔塞尔过敏反应的发生率
Rebecca Symons1,2, Fiona Heath1, Jennifer Duggan1
1Royal Hospital for Women, Randwick, NSW, Australia.
概括
引入修改后的马克曼脱敏疗法作为帕克利塔塞尔的主要预防措施,并没有降低过敏反应的发生率或严重程度. 然而,所有患者都能成功地重新接受帕克利塔塞尔.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 帕克利塔塞尔是治疗妇科恶性瘤的关键化疗剂.
- 帕克利塔塞尔过敏反应 (PHRs) 可能是严重的,需要修改治疗.
- 马克曼的脱敏方案是为治疗已建立的PHRs而建立的.
研究的目的:
- 为了评估PHRs的初级预防中修改过的Markman脱敏化方案的疗效.
- 为了减少对帕克利塔塞尔过敏反应的发生率和严重程度.
- 为了评估帕克利塔克塞尔的安全性和成功率,在反应后重新挑战.
主要方法:
- 对接受帕克利塔塞尔治疗的妇科恶性瘤患者进行了回顾性评估.
- 该研究比较了实施修改后的马克曼脱敏方案之前和之后的结果.
- 分析了帕克利塔克塞尔的剂量和过敏反应的严重程度.
主要成果:
- 帕克利塔克塞尔过敏反应的发生率相似:在实施前为8%,在实施后为9% (p=0.87).
- 大多数反应都是2级,两组都在30分钟内发生.
- 在实施后100%的患者实现了成功的帕克利塔克塞尔再试验,而在实施前为81%.
结论:
- 经过修改的马克曼的协议没有显著降低率或严重度的帕克利塔克塞尔过敏反应当作为主要预防使用时.
- 该协议在所有患者中都促进了成功的复试.
- 可能需要进一步的研究来优化对帕克利塔克塞尔过敏的预防策略.
相关概念视频
02:06Allergic Reactions
Overview
01:27Allergic Drug Reactions
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
01:30Drug Toxicity: Allergic Reactions
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
01:30Allergic Reactions: Anaphylaxis
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...
01:01Hypersensitivity Reactions: Cytolytic Reactions
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
01:29Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...